https://orcid.org/0000-0003-2427-915X
References
- Sarasquete M, Garcia-Sanz R, Gonzalez D, et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica. 2005;90(10):1365–1372.
- Silvennoinen R, Lundan T, Kairisto V, et al. Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma. Blood Cancer J. 2014;4:e250. doi: 10.1038/bcj.2014.69
- Ladetto M, Ferrero S, Drandi D, et al. Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma. Leukemia. 2016;30(5):1211–1214. doi: 10.1038/leu.2015.269
- Ladetto M, Donovan JW, Harig S, et al. Real-Time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma. Biol Blood Marrow Transplant. 2000;6(3):241–253. doi: 10.1016/S1083-8791(00)70006-1
- Rasmussen T, Poulsen TS, Honore L, et al. Quantitation of minimal residual disease in multiple myeloma using an allele-specific real-time PCR assay. Exp Hematol. 2000;28(9):1039–1045. doi: 10.1016/S0301-472X(00)00514-2
- Posel C, Moller K, Frohlich W, et al. Density gradient centrifugation compromises bone marrow mononuclear cell yield. PLoS One. 2012;7(12):e50293. doi: 10.1371/journal.pone.0050293
- Bai Y, Wong KY, Fung TK, et al. High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers/probes. J Hematol Oncol. 2016;9(1):107. doi: 10.1186/s13045-016-0336-4
- van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17(12):2257–2317. doi: 10.1038/sj.leu.2403202
- Verhagen OJ, Willemse MJ, Breunis WB, et al. Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia. Leukemia. 2000;14(8):1426–1435. doi: 10.1038/sj.leu.2401801
- van der Velden VH, de Bie M, van Wering ER, et al. Immunoglobulin light chain gene rearrangements in precursor-B-acute lymphoblastic leukemia: characteristics and applicability for the detection of minimal residual disease. Haematologica. 2006;91(5):679–682.
- van der Velden VH, Cazzaniga G, Schrauder A, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007;21(4):604–611. doi: 10.1038/sj.leu.2404586
- Korthals M, Sehnke N, Kronenwett R, et al. The level of minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood stem cell transplantation is an independent predictive parameter. Biol Blood Marrow Transplant. 2012;18(3):423–431. doi: 10.1016/j.bbmt.2011.07.002
- Puig N, Sarasquete ME, Balanzategui A, et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. Leukemia. 2014;28(2):391–397. doi: 10.1038/leu.2013.217